Form 4: Enliven Therapeutics' Chief Scientific Officer Exercises Options and Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on February 29, 2024, according to a Form 4 filing with the SEC.

Summary

• On February 29, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, exercised options to purchase 12,000 shares of common stock at a price of $1.12 per share.
• He then sold 10,195 shares at a weighted average price of $16.2974 and 1,805 shares at a weighted average price of $17.0938.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Lyssikatos directly holds 0 shares and indirectly holds 1,117,035 shares through The Lyssikatos Revocable Trust 12/15/2011.
• He also directly holds options for 272,550 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are pursuant to a pre-arranged trading plan, which mitigates concerns about opportunistic trading.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates